Sign in Subscribe

Alex Chompff

Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer An indirect comparison using reconstructed patient data from KEYNOTE-177 and CheckMate 8HW suggests nivolumab-ipilimumab may offer progression-free survival benefits over pembrolizumab in first-line MSI-H/dMMR metastatic disease, though grade 3/4

Inflammation may limit muscle-building benefits of high-protein nutrition during treatment

Skip to content The CRC Digest ♥ LIVING WITH CRC Inflammation may limit muscle-building benefits of high-protein nutrition during treatment A post-hoc analysis of the PRIMe trial found that baseline systemic inflammation influenced the effectiveness of high-protein nutritional support to increase lean soft tissue in patients with stage II-IV colorectal cancer.

TAP1 deficiency creates new immunotherapy targets in colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH TAP1 deficiency creates new immunotherapy targets in colorectal cancer Loss of TAP1, an immune escape mechanism found in 26% of colorectal cancers, generates alternative T cell epitopes that may be exploitable for immunotherapy; researchers identified CD8 T cells from patient tumors that can

Targeting peripheral serotonin receptor enhances antitumor immunity in colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Targeting peripheral serotonin receptor enhances antitumor immunity in colorectal cancer Researchers developed IHCH-8110, a non-brain-penetrant 5-HT2AR agonist that activates serotonin receptors on enteric glial cells to promote CD8+ T cell recruitment and suppress colorectal cancer growth without psychedelic effects. (Cell) This content is

AHN researchers help develop blood test that detects colorectal cancer and high-risk polyps

Skip to content The CRC Digest ▪ SCREENING AHN researchers help develop blood test that detects colorectal cancer and high-risk polyps Researchers at Allegheny Health Network contributed to development of a blood-based screening test capable of detecting both colorectal cancer and high-risk polyps. (Beaver County Radio) This content is informational only

CRC Research Update — August 11, 2026

Today's colorectal cancer research highlights

Systematic review identifies factors affecting cancer screening participation among survivors

Skip to content The CRC Digest Systematic review identifies factors affecting cancer screening participation among survivors A meta-analysis examined predictors of participation in breast and colorectal cancer screening among cancer survivors, who are at increased risk of subsequent primary cancers but show suboptimal screening uptake. (Journal of Cancer Survivorship) This

Qualitative study explores barriers and facilitators to exercise in older adults with colorectal cancer

Skip to content The CRC Digest Qualitative study explores barriers and facilitators to exercise in older adults with colorectal cancer Researchers interviewed patients aged 75 years or older with CRC scheduled for elective surgery to understand what helps or hinders participation in physical exercise during the perioperative period, noting that

Economic evaluation compares nivolumab plus ipilimumab versus nivolumab alone in dMMR/MSI-H metastatic CRC

Skip to content The CRC Digest Economic evaluation compares nivolumab plus ipilimumab versus nivolumab alone in dMMR/MSI-H metastatic CRC A Chinese study used a three-state partitioned survival model to evaluate nivolumab plus ipilimumab versus nivolumab monotherapy in previously treated metastatic colorectal cancer patients with dMMR/MSI-H, using Kaplan-Meier curves

Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer

Skip to content The CRC Digest ▸ TREATMENT Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer A patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer responded to re-challenge with encorafenib and cetuximab combined with nivolumab after prior progression, suggesting this combination may offer renewed